Study of an oxalate-lowering medicine for PH1 and kidney failure
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are between newborn and under 6 years old for this study
- You have PH1 (primary hyperoxaluria type 1) confirmed by genetic testing
- Your kidney function is low, with an estimated GFR under 30 (adjusted for body size)
- Your recent blood oxalate level is high (average over 20 micromoles per liter) during screening
- If you use dialysis, your dialysis plan has been stable for at least 2 weeks and dialysis duration is under 24 months
- You can follow the study rules and complete study visits (with consent from a parent/guardian if under 18)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
This trial tests a medication called stiripentol to see if it can lower oxalate levels in people with primary hyperoxaluria (types 1, 2, or 3). It may help prevent kidney stones and protect kidney function.
This Phase 3 trial studies how well a new peritoneal dialysis solution works and whether it is safe. It’s meant for adults with kidney failure who already do a specific type of at-home dialysis.
This study tests a new investigational drug called KK8123 for adults with X-linked hypophosphatemia (XLH). It aims to see if KK8123 can safely raise low blood phosphorus levels. The trial includes two parts and may offer a new treatment option if you have not used burosumab recently.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
Hear when a new Primary Hyperoxaluria Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.